Cargando…

Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects

Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangwar, Shailendra Kumar, Kumar, Aviral, Yap, Kenneth Chun-Hong, Jose, Sandra, Parama, Dey, Sethi, Gautam, Kumar, Alan Prem, Kunnumakkara, Ajaikumar B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145966/
https://www.ncbi.nlm.nih.gov/pubmed/35631448
http://dx.doi.org/10.3390/ph15050624
_version_ 1784716444714401792
author Gangwar, Shailendra Kumar
Kumar, Aviral
Yap, Kenneth Chun-Hong
Jose, Sandra
Parama, Dey
Sethi, Gautam
Kumar, Alan Prem
Kunnumakkara, Ajaikumar B.
author_facet Gangwar, Shailendra Kumar
Kumar, Aviral
Yap, Kenneth Chun-Hong
Jose, Sandra
Parama, Dey
Sethi, Gautam
Kumar, Alan Prem
Kunnumakkara, Ajaikumar B.
author_sort Gangwar, Shailendra Kumar
collection PubMed
description Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, controlling smoking alone has a significant value as a preventive measure. In spite of decades of extensive research, mechanistic cues and targets need to be profoundly explored to develop potential diagnostics, treatments, and reliable therapies for this disease. Nuclear receptors (NRs) function as transcription factors that control diverse biological processes such as cell growth, differentiation, development, and metabolism. The aberrant expression of NRs has been involved in a variety of disorders, including cancer. Deregulation of distinct NRs in lung cancer has been associated with numerous events, including mutations, epigenetic modifications, and different signaling cascades. Substantial efforts have been made to develop several small molecules as agonists or antagonists directed to target specific NRs for inhibiting tumor cell growth, migration, and invasion and inducing apoptosis in lung cancer, which makes NRs promising candidates for reliable lung cancer therapeutics. The current work focuses on the importance of various NRs in the development and progression of lung cancer and highlights the different small molecules (e.g., agonist or antagonist) that influence NR expression, with the goal of establishing them as viable therapeutics to combat lung cancer.
format Online
Article
Text
id pubmed-9145966
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91459662022-05-29 Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects Gangwar, Shailendra Kumar Kumar, Aviral Yap, Kenneth Chun-Hong Jose, Sandra Parama, Dey Sethi, Gautam Kumar, Alan Prem Kunnumakkara, Ajaikumar B. Pharmaceuticals (Basel) Review Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, controlling smoking alone has a significant value as a preventive measure. In spite of decades of extensive research, mechanistic cues and targets need to be profoundly explored to develop potential diagnostics, treatments, and reliable therapies for this disease. Nuclear receptors (NRs) function as transcription factors that control diverse biological processes such as cell growth, differentiation, development, and metabolism. The aberrant expression of NRs has been involved in a variety of disorders, including cancer. Deregulation of distinct NRs in lung cancer has been associated with numerous events, including mutations, epigenetic modifications, and different signaling cascades. Substantial efforts have been made to develop several small molecules as agonists or antagonists directed to target specific NRs for inhibiting tumor cell growth, migration, and invasion and inducing apoptosis in lung cancer, which makes NRs promising candidates for reliable lung cancer therapeutics. The current work focuses on the importance of various NRs in the development and progression of lung cancer and highlights the different small molecules (e.g., agonist or antagonist) that influence NR expression, with the goal of establishing them as viable therapeutics to combat lung cancer. MDPI 2022-05-18 /pmc/articles/PMC9145966/ /pubmed/35631448 http://dx.doi.org/10.3390/ph15050624 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gangwar, Shailendra Kumar
Kumar, Aviral
Yap, Kenneth Chun-Hong
Jose, Sandra
Parama, Dey
Sethi, Gautam
Kumar, Alan Prem
Kunnumakkara, Ajaikumar B.
Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title_full Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title_fullStr Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title_full_unstemmed Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title_short Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
title_sort targeting nuclear receptors in lung cancer—novel therapeutic prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145966/
https://www.ncbi.nlm.nih.gov/pubmed/35631448
http://dx.doi.org/10.3390/ph15050624
work_keys_str_mv AT gangwarshailendrakumar targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT kumaraviral targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT yapkennethchunhong targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT josesandra targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT paramadey targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT sethigautam targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT kumaralanprem targetingnuclearreceptorsinlungcancernoveltherapeuticprospects
AT kunnumakkaraajaikumarb targetingnuclearreceptorsinlungcancernoveltherapeuticprospects